OasisLMS

Biomarker Basics for Urologic Advanced Practice Providers series includes two 90-minute live webinars featuring a multidisciplinary panel, including perspectives from a Urologist and Genetic Counselor, Physician Assistant and Nurse Practitioner.

Designed for urologic advanced practice providers this interactive series will discuss current guidelines for biomaker and genetic testing, how to incorporate testing into your clinical care pathways, interpret profiling reports, and integrate results into the shared-decision making process for prostate cancer patients. 

Part 1: Tuesday, June 23, 2026 from 7:00-8:30 p.m. Eastern
Part 2: Tuesday, June 7, 2026 from 7:00-8:30 p.m. Eastern

Course Director: Kara Cossis, PA-C, MPH

Acknowledgements
Support provided by independent educational grants from:

• Pfizer, Inc. 

• Advanced Practice Providers

PART 1:

After participating in this CME activity, participants will be able to:

1. Apply guideline-concordant biomarker and genetic testing practices—including the role of germline and somatic alterations—when evaluating patients with urologic cancers during initial diagnostic workup.
2. Differentiate the clinical significance of commonly used biomarkers and genetic tests in prostate cancer to guide therapy selection and align with NCCN guideline recommendations.
3. Implement best practices for clinical care pathways that incorporate routine and rapid testing in prostate cancer to optimize timeliness of treatment decisions across different practice settings.
4. Engage patients and multidisciplinary team members in shared decision-making to integrate biomarker and genetic test results into individualized care plans for prostate cancer management.

PART 2:

After participating in this CME activity, participants will be able to:

1. Interpret molecular profiling reports to identify clinically actionable alterations and stratify prostate cancer patients for guideline-based treatment decisions.
2. Differentiate between germline and somatic test results to accurately determine hereditary versus tumor-specific implications in patients undergoing biomarker and genetic testing.
3. Integrate biomarker and genetic testing results into patient-centered clinical discussions to help patients and caregivers understand the therapeutic, prognostic, and familial implications of findings.
4. Apply communication strategies for explaining molecular profiling results to facilitate shared decision-making and align treatment planning with patient values and preferences.

FACULTY DISCLOSURES

Coming soon

EDUCATION COUNCIL DISCLOSURE

Education Council DTL 2025.pdf

COI REVIEW WORK GROUP DISCLOSURES

COI Review Workgroup DTL 2025.pdf

AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.

ACCREDITATION:

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION:

The American Urological Association designates each live activity for a maximum of 1.50 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

OTHER LEARNERS:

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credits^TM.

EVIDENCE BASED CONTENT:

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY:

All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individual s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of relevant financial relationships that result in conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

AUA PARTICIPANT INFORMATION & POLICIES

Disclaimer: 
The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission: 
Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.